Uric acid and cardiovascular disease: A clinical review

“…We and other groups have previously shown the SUA level as a marker or predictor of systemic endothelial dysfunction in patients with ACS and INOCA [ 6 , 7 , 8 ], and the present study supported the concept in the entire spectrum of IHD. While numerous epidemiological studies have reported the association of the SUA level with cardiovascular disease, including IHD [ 5 ], a therapeutic intervention targeting SUA in IHD has not been fully investigated. Noman et al previously demonstrated that in CCS patients with angiographically confirmed obstructive CAD, allopurinol (600 mg/day) significantly improved exercise capacity in a randomized, placebo-controlled, cross-over setting [ 29 ].…”

“…Uric acid, the end-product of purine metabolism in humans, is associated with inflammation, oxidative stress, and endothelial dysfunction, contributing to the development of atherosclerotic diseases including IHD [ 5 ]. Previous studies have indicated that urate lowering therapy had an effect on blood pressure and endothelial function [ 5 ], and we and others have reported that the serum uric acid (SUA) level was a marker or predictor of systemic endothelial dysfunction in patients with ACS and INOCA [ 6 , 7 , 8 ]. However, whether the SUA level is associated with impaired endothelial function in patients with a broad spectrum of IHD is unclear.…”